Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranolazine Monotherapy in Type 2 Diabetes
NCT01472185Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Nov 2011
- Primary completion
- Oct 2013
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 3 trial of ranolazine in type 2 diabetes mellitus (T2DM), sponsored by Gilead Sciences. Started Nov 2011; status: completed.
02
Drugs
ranolazine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01472185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01472185.